The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy

ConclusionsIt was determined that Ankaferd hemostat is effective in preventing oral mucositis due to chemotherapy in adult patients diagnosed with colorectal cancer. In addition, it has been suggested to conduct new studies on the effectiveness of Ankaferd hemostat in the prevention of mucositis in different groups.Trial registrationThe study was registered at ClinicalTrials.gov (ID: NCT05438771, Date: 25.06.2022).
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research